Navigation Links
Resverlogix Share Option Extension
Date:4/21/2008

TSX Exchange Symbol: RVX

CALGARY, April 21 /PRNewswire-FirstCall/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that 948,700 stock options due to expire April 25, 2008 will automatically be extended pursuant to the Company's stock option plan and in accordance with TSX Staff Notice 2006-0001. The Company's stock option plan provides that in the event that stock options would otherwise expire during a "blackout" trading restriction imposed by the Company under its Corporate Governance Policy, then such options shall be extended until 10 business days following the date the black out period is lifted by the Company. This is to give the option holders fair and reasonable opportunity to exercise their options.

While it is not the Company's normal policy to publicize blackout dates, given the significant number of options in question and the fact they are held by directors and senior officers of the Company, Resverlogix desired to clarify the options' status to ensure the market was not in any way misled. It is not known at this time when the blackout period will be lifted.

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet needs. The NexVas(TM) program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-I. These vital therapies address the grievous burden of atherosclerosis and other important diseases such as acute coronary syndrome, diabetes, Alzheimer's and other vascular disorders. The Company's secondary focus is TGF-Beta Shield(TM), a program that aims to address burgeoning grievous diseases, such as cancer and fibrosis. Resverlogix Corp. trades on the Toronto Stock Exchange (TSX:RVX). For further information please visit http://www.resverlogix.com.

This news release may contain certain forward-looking statements that reflect the current views and/or expectations of Resverlogix Corp. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly. The TSX Exchange does not accept responsibility for the adequacy or accuracy of this news release.


'/>"/>
SOURCE Resverlogix Corp.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. FDA Grants Resverlogix Approval to Commence a Phase 1 Clinical Trial for RVX-208
2. Resverlogix Honoured with World Economic Forum Technology Pioneer Award
3. Resverlogix is Presenting at IAS HDL Workshop
4. Resverlogix Presents Key Apo-Al/HDL Scientific Data at DALM
5. Investors Acquire Share in Sangui BioTech GmbH
6. BioMed Realty Trust Prices Public Offering of 5,700,000 Shares of Common Stock
7. Chromos provides shareholder update
8. Arpida Announces Agenda Items for Shareholders Meeting
9. Pharmaceuticals & Biotechs to Share Insights for Developing Leaders in a Fast-Paced, Competitive Industry
10. Takeda to Acquire Millennium for US$25.00 Per Share in an All Cash Tender Offer Valued at $8.8 Billion
11. ARIUS 2008 Annual and Special Meeting of Shareholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... December 01, 2016 , ... ... Nanowear on their recent FDA Class II 510(k) clearance for their flagship medical ... in commercializing remote cardiac monitoring devices that rely on cloth-based nanosensors. While other ...
(Date:12/2/2016)... bioLytical Laboratories, a world leader in rapid infectious disease tests, introduced the Company,s newest ... members. (Photo: http://photos.prnewswire.com/prnh/20161201/444905 ) Continue Reading ... ... , , bioLytical was invited ... introduce the INSTI HIV Self Test to 350 pharmacy representatives in Nairobi ...
(Date:11/30/2016)... 2016 Biotest Pharmaceuticals Corporation (BPC), a leading ... the addition of its newest plasma collection center located ... . The 15,200 square foot state-of-the-art facility officially opened ... brings the total number of BPC,s plasma collection centers ... BPC,s Chief Executive Officer said "We are pleased to ...
(Date:11/30/2016)... , 30. November 2016   Merck ... heute die Unterzeichnung einer Reihe von Vereinbarungen ... wird Evotec AG Screeningleistungen für Mercks Palette ... Der Zugriff auf diese Bibliotheken in Kombination ... einen schnelleren Weg zur Ermittlung und Erforschung ...
Breaking Biology Technology:
(Date:11/29/2016)... -- BioDirection, a privately held medical device company developing ... of concussion and other traumatic brain injury (TBI), announced ... with the U.S. Food and Drug Administration (FDA) to ... the meeting company representatives reviewed plans for clinical development ... of a planned pilot trial. "We ...
(Date:11/29/2016)... CANNES, France , November 29, 2016 Nearly ... Continue Reading ... ... System is part of an efficient Identity Management. (PRNewsFoto/DERMALOG Identification Systems) ... DERMALOG is Germany's largest Multi-Biometric ...
(Date:11/24/2016)... Calif. , Nov. 23, 2016 Cercacor ... endurance athletes and their trainers non-invasively measure ... Index, Pulse Rate, and Respiration Rate in approximately 30 ... enables users easy and immediate access to key data ... part of a training regimen. Hemoglobin ...
Breaking Biology News(10 mins):